UNSPSC 51171646: Alvimopan anhydrous

This classification denotes the anhydrous form of an opiate antagonist with the molecular formula C25H32N2O4.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 677C126AET, chemically known as glycine, n-((2s)-2-(((3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-, dihydrate but more generally known as alvimopan, which bears US NIH Compound Identifier 5488547. Alvimopan most often comes in simple, anhydrous, and hyrdate forms.

UNSPSC 51171646 Alvimopan anhydrous is a Commodity code that should track pharmaceutical active pharmaceutical ingredients and finished-dose medications, but recent state and local solicitations tagged with this code show limited direct relevance to alvimopan specifically. The code appears in a fragmented procurement environment where state and local bodies acquire pharmaceuticals, OTC products, and related clinical services through cooperative purchasing alliances, department health programs, and county criminal-justice agencies. Issuing bodies include state health and human services commissions, multistate cooperative purchasing organizations, and county community supervision departments. The work being solicited spans generic pharmaceutical supply contracting, specialty clinical testing services with pharmaceutical components, and direct-to-manufacturer prescription program development, though none of the recent opportunities explicitly name alvimopan as a line item.

Recent activity concentrates in Texas and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities across multiple states including Oregon, with contracts effective July 1, 2026 and a two-year initial term. Collin County Community Supervision and Corrections Department in Texas issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals, which involves pharmaceutical testing methodologies but not alvimopan procurement per se. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in late March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling future formal pharmaceutical procurement solicitations. The code shows pharmaceutical procurement activity but limited direct alignment with alvimopan-specific contracting opportunities in the recent record.